Skip to main content
SpringerLink
Log in
Book cover

Bone Metastases pp 419–439Cite as

Outcome Measures in Bone Metastases Clinical Trials

  • Chapter
  • First Online:

  • 1740 Accesses

Part of the book series: Cancer Metastasis - Biology and Treatment ((CMBT,volume 21))

Abstract

The most common site of metastatic disease in advanced cancer is bone. Management of bone metastases is becoming increasingly multi-disciplinary in nature and many advances have been made to both localized and systemic therapies. With the expanding body of literature, it is important to recognize that there is still extensive variation in response or outcome definitions, and that standardization and consensus of how to analyze clinical data is needed. This will ensure that therapy options can be accurately monitored for both their benefits and adverse effects and allow for better cross-study comparisons. This chapter will outline the outcomes of interest in radiation and bone-modifying agent clinical trials, as well as introduce outcomes used in pain flare and radiation induced nausea and vomiting assessment. The evaluation of pain response in previous trials and the establishment of the International Bone Metastases Consensus Working Party endpoints will also be presented.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090

    PubMed  CAS  Google Scholar 

  2. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6(3):163–174

    PubMed  CAS  Google Scholar 

  3. Brown JE, Coleman RE (2002) The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 4(1):24–29

    PubMed  CAS  Google Scholar 

  4. Chow E, Harris K, Fan G et al (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25(11):1423–1436

    PubMed  Google Scholar 

  5. Sze WM, Shelley MD, Held I et al (2003) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy—a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 15(6):345–352

    CAS  Google Scholar 

  6. Wu JS, Wong R, Johnston M et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55(3):594–605

    PubMed  Google Scholar 

  7. Coia LR, Hanks GE, Martz K et al (1988) Practice patterns of palliative care for the United States 1984–1985. Int J Radiat Oncol Biol Phys 14(6):1261–1269

    PubMed  CAS  Google Scholar 

  8. Priestman TJ, Dunn J, Brada M et al (1996) Final results of the Royal College of Radiologists’ trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 8(5):308–315

    CAS  Google Scholar 

  9. Crellin AM, Marks A, Maher EJ (1989) Why don’t British radiotherapists give single fractions of radiotherapy for bone metastases? Clin Oncol (R Coll Radiol) 1(2):63–66

    CAS  Google Scholar 

  10. Lawton PA, Maher EJ (1991) Treatment strategies for advanced and metastatic cancer in Europe. Radiother Oncol 22(1):1–6

    PubMed  CAS  Google Scholar 

  11. Maher EJ, Coia L, Duncan G et al (1992) Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys 23(1):239–244

    PubMed  CAS  Google Scholar 

  12. Duncan G, Duncan W, Maher EJ (1993) Patterns of palliative radiotherapy in Canada. Clin Oncol (R Coll Radiol) 5(2):92–97

    CAS  Google Scholar 

  13. Stevens G, Firth I (1995) Patterns of fractionation for palliation of bone metastases. Australas Radiol 39(1):31–35

    PubMed  CAS  Google Scholar 

  14. Ben-Josef E, Shamsa F, Williams AO et al (1998) Radiotherapeutic management of osseous metastases: a survey of current patterns of care. Int J Radiat Oncol Biol Phys 40(4):915–921

    PubMed  CAS  Google Scholar 

  15. Chow E, Danjoux C, Wong R et al (2000) Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol 56(3):305–314

    PubMed  CAS  Google Scholar 

  16. Lievens Y, Kesteloot K, Rijnders A et al (2000) Differences in palliative radiotherapy for bone metastases within Western European countries. Radiother Oncol 56(3):297–303

    PubMed  CAS  Google Scholar 

  17. Roos DE (2000) Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: an Australian and New Zealand practice survey and literature review. Radiother Oncol 56(3):315–322

    PubMed  CAS  Google Scholar 

  18. Moller TR, Brorsson B, Ceberg J et al (2003) A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 42(5–6):387–410

    PubMed  Google Scholar 

  19. Gupta T, Sarin R (2004) Palliative radiation therapy for painful vertebral metastases: a practice survey. Cancer 101(12):2892–2896

    PubMed  Google Scholar 

  20. Wu JS, Bezjak A, Chow E et al (2002) Primary treatment endpoint following palliative radiotherapy for painful bone metastases: need for a consensus definition? Clin Oncol (R Coll Radiol) 14(1):70–77

    Google Scholar 

  21. Kirkbride P, Warde P, Panzarella T et al (2000) A randomised trial comparing the efficacy and safety of single fraction radiation therapy plus Ondansetron with fractionated therapy in the palliation of skeletal metastases [Abstract]. Int J Rad Oncol Biol Phys 48(3):185, Suppl

    Google Scholar 

  22. Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 50(5):893–899

    PubMed  CAS  Google Scholar 

  23. Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55(7):1468–1472

    PubMed  CAS  Google Scholar 

  24. Nielsen OS, Bentzen SM, Sandberg E et al (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47(3):233–240

    PubMed  CAS  Google Scholar 

  25. Chow E, Hoskin P, Mitera G et al (2012) Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys 82(5):1730–1737

    PubMed  Google Scholar 

  26. Chow E, Wu JS, Hoskin P et al (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64(3):275–280

    PubMed  Google Scholar 

  27. Mor V, Laliberte L, Morris JN et al (1984) The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 53(9):2002–2007

    PubMed  CAS  Google Scholar 

  28. Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45(8):2220–2224

    PubMed  CAS  Google Scholar 

  29. Chow E, Harth T, Hruby G et al (2001) How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 13(3):209–218

    CAS  Google Scholar 

  30. Vigano A, Dorgan M, Buckingham J et al (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14(5):363–374

    PubMed  CAS  Google Scholar 

  31. Expert Advisory Committee on the Management of Severe Chronic Pain in Cancer Patients (Canada), Begin M, Canada. Health, Welfare Canada. Cancer Pain: A Monograph on the Management of Cancer Pain : a Report of the Expert Advisory Committee on the Management of Severe Chronic Pain in Cancer Patients to the Honourable Monique Begin. : Health and Welfare Canada; 1986

    Google Scholar 

  32. Miaskowski C (2005) The next step to improving cancer pain management. Pain Manag Nurs 6(1):1–2

    PubMed  Google Scholar 

  33. Harris K, Li K, Flynn C et al (2007) Worst, average or current pain in the brief pain inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol (R Coll Radiol) 19(7):523–527

    CAS  Google Scholar 

  34. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 23(2):129–138

    PubMed  CAS  Google Scholar 

  35. Ger LP, Ho ST, Sun WZ et al (1999) Validation of the brief pain inventory in a Taiwanese population. J Pain Symptom Manage 18(5):316–322

    PubMed  CAS  Google Scholar 

  36. Wu JS, Monk G, Clark T et al (2006) Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol) 18(7):539–544

    CAS  Google Scholar 

  37. McMillan SC, Tittle M, Hagan S et al (2000) Management of pain and pain-related symptoms in hospitalized veterans with cancer. Cancer Nurs 23(5):327–336

    PubMed  CAS  Google Scholar 

  38. Serlin RC, Mendoza TR, Nakamura Y et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284

    PubMed  CAS  Google Scholar 

  39. Anderson KO (2005) Role of cutpoints: why grade pain intensity? Pain 113(1–2):5–6

    PubMed  Google Scholar 

  40. Clark P, Lavielle P, Martinez H (2003) Learning from pain scales: patient perspective. J Rheumatol 30(7):1584–1588

    PubMed  Google Scholar 

  41. Gordon DB, Dahl JL, Miaskowski C et al (2005) American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 165(14):1574–1580

    PubMed  Google Scholar 

  42. National Comprehensive Cancer Network (2008) NCCN clinical practice guidelines in oncology: adult cancer pain V.1.2006. http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Accessed 15 Aug 2008

  43. Li KK, Harris K, Hadi S et al (2007) What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 10(6):1338–1346

    PubMed  Google Scholar 

  44. Li KK, Hadi S, Kirou-Mauro A et al (2008) When should we define the response rates in the treatment of bone metastases by palliative radiotherapy? Clin Oncol (R Coll Radiol) 20(1):83–89

    CAS  Google Scholar 

  45. Brunelli C, Costantini M, Di Giulio P et al (1998) Quality-of-life evaluation: when do terminal cancer patients and health-care providers agree? J Pain Symptom Manage 15(3):151–158

    PubMed  CAS  Google Scholar 

  46. Grossman SA, Sheidler VR, Swedeen K et al (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 6(2):53–57

    PubMed  CAS  Google Scholar 

  47. Higginson IJ, McCarthy M (1993) Validity of the support team assessment schedule: do staffs’ ratings reflect those made by patients or their families? Palliat Med 7(3):219–228

    PubMed  CAS  Google Scholar 

  48. Higginson IJ (1998) Can professionals improve their assessments? J Pain Symptom Manage 15(3):149–150

    PubMed  CAS  Google Scholar 

  49. Nekolaichuk CL, Bruera E, Spachynski K et al (1999) A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 13(4):311–323

    PubMed  CAS  Google Scholar 

  50. Slevin ML, Plant H, Lynch D et al (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57(1):109–112

    PubMed  CAS  Google Scholar 

  51. Sneeuw KC, Aaronson NK, Sprangers MA et al (1997) Value of caregiver ratings in evaluating the quality of life of patients with cancer. J Clin Oncol 15(3):1206–1217

    PubMed  CAS  Google Scholar 

  52. Sprangers MA, Aaronson NK (1992) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 45(7):743–760

    PubMed  CAS  Google Scholar 

  53. Chow E, Ling A, Davis L et al (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother Oncol 75(1):64–69

    PubMed  Google Scholar 

  54. Chow E, Hird A, Wong R et al (2010) Validation of meaningful change in pain scores in the treatment of bone metastases. In: Chow E, Merrick J (eds) Pain and quality of life. Nova Science Publishers, New York

    Google Scholar 

  55. Hartsell WF, Scott CB, Bruner DW et al (2005) Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97(11):798–804

    PubMed  Google Scholar 

  56. Steenland E, Leer JW, van Houwelingen H et al (1999) The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52(2):101–109

    PubMed  CAS  Google Scholar 

  57. Lenert LA, Treadwell JR, Schwartz CE (1999) Associations between health status and utilities implications for policy. Med Care 37(5):479–489

    PubMed  CAS  Google Scholar 

  58. Chow E, Chiu H, Doyle M et al (2007) Patient expectation of the partial response and response shift in pain score. Support Cancer Ther 4(2):110–118

    PubMed  Google Scholar 

  59. Farrar JT, Berlin JA, Strom BL (2003) Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 25(5):406–411

    PubMed  Google Scholar 

  60. Major PP, Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 25(6 Suppl 1):S10–S18

    PubMed  Google Scholar 

  61. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132

    PubMed  CAS  Google Scholar 

  62. Saad F, Chen YM, Gleason DM et al (2007) Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 5(6):390–396

    PubMed  CAS  Google Scholar 

  63. Paterson AH, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1):59–65

    PubMed  CAS  Google Scholar 

  64. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468

    PubMed  CAS  Google Scholar 

  65. Major P, Cook R (2004) Clinical endpoints for assessing bisphosphonate efficacy in the prevention of skeletal complications of bone metastases. Eur Urol Suppl 3(5):334–339

    Google Scholar 

  66. Johnson JR, Williams G, Pazdur R (2003) End points and United States food and drug administration approval of oncology drugs. J Clin Oncol 21(7):1404–1411

    PubMed  Google Scholar 

  67. Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17(3):846–854

    PubMed  CAS  Google Scholar 

  68. Tripathy D, Lichinitzer M, Lazarev A et al (2004) Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15(5):743–750

    PubMed  CAS  Google Scholar 

  69. Zaghloul MS, Boutrus R, El-Hossieny H et al (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15(4):382–389

    PubMed  CAS  Google Scholar 

  70. Clemons M, Dranitsaris G, Cole D et al (2006) Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 11(3):227–233

    PubMed  CAS  Google Scholar 

  71. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387

    PubMed  CAS  Google Scholar 

  72. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14(9):1399–1405

    PubMed  Google Scholar 

  73. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321

    PubMed  CAS  Google Scholar 

  74. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98(5):962–969

    PubMed  CAS  Google Scholar 

  75. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21(16):3150–3157

    PubMed  CAS  Google Scholar 

  76. Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1):36–43

    PubMed  CAS  Google Scholar 

  77. Saad F (2005) Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4(1):31–37

    PubMed  CAS  Google Scholar 

  78. Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139

    PubMed  CAS  Google Scholar 

  79. Scott M, Mocks J, Givens S et al (2003) Morbidity measures in the presence of recurrent composite endpoints. Pharm Stat 2:39–49

    Google Scholar 

  80. Moecks J, Koch GG, Scott M et al (2004) Measures of morbidity in clinical studies with recurrent skeletal complications. J Biopharm Stat 14(2):415–437

    PubMed  Google Scholar 

  81. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822

    PubMed  CAS  Google Scholar 

  82. Diel IJ, Body JJ, Lichinitser MR et al (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40(11):1704–1712

    PubMed  CAS  Google Scholar 

  83. Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3):306–312

    PubMed  CAS  Google Scholar 

  84. Groff L, Zecca E, De Conno F et al (2001) The role of disodium pamidronate in the management of bone pain due to malignancy. Palliat Med 15(4):297–307

    PubMed  CAS  Google Scholar 

  85. Matza LS, Fallowfield LJ, Chung KC et al (2012) Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Support Care Cancer 20(4):657–677

    PubMed  Google Scholar 

  86. Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34(12):585–597

    PubMed  CAS  Google Scholar 

  87. Kristensen B, Ejlertsen B, Groenvold M et al (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74

    PubMed  CAS  Google Scholar 

  88. Dearnaley DP, Mason MD, Parmar MK et al (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10(9):872–876

    PubMed  CAS  Google Scholar 

  89. Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335(24):1785–1791

    PubMed  CAS  Google Scholar 

  90. Zheng M (2005) Letter to the editor: comment on ‘morbidity measures in the presence of recurrent composite endpoints’, Scott M, M.ocks J, Givens S, et al. Pharm Stat 2003; 2(1):39–49

    Google Scholar 

  91. Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16(2):593–602

    PubMed  CAS  Google Scholar 

  92. Pelger RC, Soerdjbalie-Maikoe V, Hamdy NA (2001) Strategies for management of prostate cancer-related bone pain. Drugs Aging 18(12):899–911

    PubMed  CAS  Google Scholar 

  93. Teske K, Daut RL, Cleeland CS (1983) Relationships between nurses’ observations and patients’ self-reports of pain. Pain 16(3):289–296

    PubMed  CAS  Google Scholar 

  94. Silberstein EB (2005) Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 35(2):152–158

    PubMed  Google Scholar 

  95. Kraeber-Bodere F, Campion L, Rousseau C et al (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27(10):1487–1493

    PubMed  CAS  Google Scholar 

  96. Roka R, Sera T, Pajor L et al (2000) Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain. Orv Hetil 141(19):1019–1023

    PubMed  CAS  Google Scholar 

  97. de Klerk JM, van het Schip AD, Zonnenberg BA et al (1996) Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 37(2):244–249

    PubMed  Google Scholar 

  98. Hird A, Chow E, Zhang L et al (2009) Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. Int J Radiat Oncol Biol Phys 75(1):193–197

    PubMed  Google Scholar 

  99. Danjoux CE, Rider WD, Fitzpatrick PJ (1979) The acute radiation syndrome. A memorial to William Michael Court-Brown. Clin Radiol 30(5):581–584

    PubMed  CAS  Google Scholar 

  100. Dennis K, Maranzano E, De Angelis C et al (2011) Radiotherapy-induced nausea and vomiting. Expert Rev Pharmacoecon Outcomes Res 11(6):685–692

    PubMed  Google Scholar 

  101. Feyer PC, Maranzano E, Molassiotis A et al (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19(Suppl):1S5–1S14

    Google Scholar 

  102. Maranzano E, De Angelis V, Pergolizzi S et al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94(1):36–41

    PubMed  Google Scholar 

  103. Maranzano E (2001) Radiation-induced emesis: a problem with many open questions. Tumori 87(4):213–218

    PubMed  CAS  Google Scholar 

  104. Olver I, Molassiotis A, Aapro M et al (2011) Antiemetic research: future directions. Support Care Cancer 19(Suppl):1S49–1S55

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, M4N 3M5, Toronto, ON, Canada

    Michael Poon M.D.(C), Liang Zeng M.D.(C) & Edward Chow MBBS, M.Sc., Ph.D., FRCPC

  2. Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, M4N 3M5, Toronto, ON, Canada

    Urban Emmenegger M.D.

Authors
  1. Michael Poon M.D.(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liang Zeng M.D.(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Urban Emmenegger M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edward Chow MBBS, M.Sc., Ph.D., FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Chow MBBS, M.Sc., Ph.D., FRCPC .

Editor information

Editors and Affiliations

  1. Radiation Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

    Vassilios Vassiliou

  2. Dept. Radiation Oncology, University of Toronto Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

    Edward Chow

  3. Dept. Radiation Oncology, University of Patras Medical School, Patras, Greece

    Dimitrios Kardamakis

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Poon, M., Zeng, L., Emmenegger, U., Chow, E. (2014). Outcome Measures in Bone Metastases Clinical Trials. In: Vassiliou, V., Chow, E., Kardamakis, D. (eds) Bone Metastases. Cancer Metastasis - Biology and Treatment, vol 21. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7569-5_23

Download citation

Publish with us

Policies and ethics

Search

Navigation